is planning to carry out a fully underwritten rights issue for further market launches and is taking steps toward listing at Nasdaq First North

Uppsala February 16, 2017. The Board of Senzime AB (publ) proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. The proceeds will be used to enable the commercialization of Senzimes products and strengthen its financial position. Concurrently Senzime is planning a listing at Nasdaq First North.

Summary of terms and relevant dates

• Senzime’s board proposes a rights issue of approximately SEK 24.4 million.

• The rights issue comprises up to 4,521,581 shares.

• The new shares are issued at a price of 5.40 SEK per share.

• The new shares are issued with preferential rights for the existing shareholders, whereby eight (8) existing shares give the right to subscribe for one (1) new share.

• The rights issue is subject to the shareholders at the Extraordinary General Meeting on March 3, 2017 approves the Board's proposal. Notice of the AGM is published in a separate press release.

• The rights issue is fully guaranteed through subscription undertakings and guarantees from the company's principal owner.

• Record date for participation in the rights issue is 10 March 2017.

• The subscription period in the rights issue takes place between 14 March 2017 28 March 2017.

Comment from the CEO Lena Söderström
"Now Senzime takes another big step towards the market. We have begun the commercialization of our product portfolio and aim to build a world-leading company in the peri- and post-operative patient monitoring. In recent months, we have signed a breakthrough agreement for the Japanese market, strengthened our organization and have ongoing discussions with potential license partners on additional markets. We face several CE markings and a broad market introduction in 2017. Growth capital will create conditions to accelerate the global commercialization of our product portfolio."

Extraordinary general meeting
The rights issue is subject to that the shareholders resolve in accordance with the board’s proposal at the Extraordinary General Meeting to be held March 3, 2017 at 09.30 in Advokatfirman Lindahl’s premises, Vaksalagatan 10, 751 42 Uppsala. The complete notice is published in a separate press release.

Change of Marketplace
The company has initiated a process to implement a listing on Nasdaq First North during the first half of 2017 to replace the company’s current listing on AktieTorget.

Important information
The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Senzime, neither from Senzime or from anyone else. A prospectus relating to the rights offering described in this press release will be prepared and submitted to the Swedish Financial Supervisory Agency (the “SFSA”). After the SFSA’s approval of the prospectus, the prospectus will be published and made available at e.g. Senzimes website. Neither the prospectus or the information in this press release may be released, published or distributed in the United States, Canada, Australia, Hong Kong, Japan, New Zealand or South Africa or any other country or any jurisdiction where such action or the offer requires registration or measures other than those under Swedish law.

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact person set out above, on February16, 2017 .

For further information, please contact: 
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact person set out above, on February16, 2017 .

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com

Subscribe

Documents & Links